The painkiller Bextra will not be allowed back on the Canadian market, Health Canada announced yesterday.

In barring the return of the drug, Health Canada is following the advice of an expert panel, which, after reviewing evidence and holding public hearings, concluded Bextra should not be sold in this country.

Bextra is a member of a class of drugs known as cox-2 inhibitors. Better known cox-2s are Celebrex, which is still sold, and Vioxx, which was pulled from worldwide markets in September 2004.

Drug maker Pfizer Canada voluntarily suspended sales of Bextra last April at the request of Health Canada.

The agency was concerned about reports the drug caused rare but potentially fatal skin reactions in addition to raising risks of cardiovascular events such as heart attack and stroke—a risk linked to all drugs in this class.

Following Pfizer’s sales suspension, Health Canada issued a stop-sale order which ensured Bextra could not be returned to the market without the department’s approval. The department has been studying data supplied by the manufacturer as part of its review of all the cox-2 drugs.

“Health Canada concluded that there is insufficient evidence to establish the safety of the drug for its recommended use,” the department said in a release.

Pfizer, which disagrees with Health Canada’s assessment of Bextra’s risk-benefit ratio, said it was disappointed by the decision.

“There are more than four million Canadians who suffer from arthritis. Bextra is an important treatment option for them and Pfizer believes it should continue to be available for those patients who could benefit from it,” the company’s statement said.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Bextra, Celebrex MDL judge sets first Bextra trial

On the heels of the $4.85 Billion Vioxx settlement, the Multi-District Litigation (MDL) Court for the...

End Conflicts on FDA Approvals

In the coming weeks, the U.S. House and Senate will have to reconcile bills they passed that give the...

Frank Woodson on the Additional Costs and Hidden...

Frank Woodson and David Miceli discuss the additional costs and hidden dangers associated with COX-2...

Cox-2 Inhibitors

What are Cox-2 inhibitors? Our law firm has been in the forefront of the effort to have all of the...

Bextra

What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as...

Consumer Group says Celebrex Ad Downplays Risks

Pfizer had stopped advertising for the arthritis drug after Merck & Co. Inc.'s rival drug Vioxx was...

Impressed with the Beasley Allen staff

I am very impressed with the Beasley Allen staff. They were very courteous and patiently explained the aspects of my claim in a way I could understand. If I ever have any need of an attorney in the future I will turn to Beasley Allen.

—Philip